Comparative effects of long-acting beta2-agonists, leukotriene receptor antagonists, and a 5-lipoxygenase inhibitor on exercise-induced asthma

Autor: Mary Skowronski, Albert Coreno, E. R. McFadden, Chakradhar Kotaru
Rok vydání: 2000
Předmět:
Zdroj: The Journal of allergy and clinical immunology. 106(3)
ISSN: 0091-6749
Popis: Background: Exercise-induced asthma (EIA) is a common problem that can be controlled with long-acting β-agonists and leukotriene-modifying compounds. There is, however, limited information on the comparative effectiveness of the two classes of drugs, as well as the relative potencies of the antileukotriene agents. Objective: The purpose of the present study was to provide data on the above issues. Methods: We performed a random-order, blinded, double-dummy, placebo-controlled trial in 10 patients with EIA. Each subject received standard single doses of salmeterol, montelukast, zafirlukast, zileuton, and placebo on separate days. The participants performed 4 minutes of cycle ergometry while breathing frigid air 1, 4, 8, and 12 hours after administration of the test agents. The primary endpoint was the extent of the decrement in the FEV 1 10 minutes after exertion. Results: With placebo, symptomatic airway narrowing developed at all times (mean ± SE decrease in FEV 1 ranged between 21% ± 5% and 26% ± 5%). Salmeterol acted quickly and significantly blunted the obstructive response for 12 hours (ΔFEV 1 first hour: 8% ± 3%; ΔFEV 1 twelfth hour: 8% ± 3%; P P = .72 vs time). The leukotriene-modifying agents produced effects within 1 hour of ingestion. Like salmeterol, montelukast and zafirlukast also offered long-lasting protection, and there were no significant differences between them (montelukast ΔFEV 1 twelfth hour: 9% ± 4%; zafirlukast ΔFEV 1 twelfth hour: 11% ± 2%; P = .75) or the β 2 -agonist (montelukast vs salmeterol: P = .72; zafirlukast vs salmeterol: P = .48). Zileuton provided equivalent prophylaxis for the first 4 hours (ΔFEV 1 fourth hour: 11% ± 2%); however, by 8 hours, it was less efficacious than all of the other active compounds, and by 12 hours it did not differ from placebo (ΔFEV 1 twelfth hour: 19% ± 4%; P = .33). Conclusions: Single doses of the currently available leukotriene receptor antagonists provide prompt effective and persistent defense against EIA that equals that seen with a long-acting β 2 -agonist. The synthesis inhibitor zileuton affords a comparable magnitude of prophylaxis but has a considerably shorter duration of action. (J Allergy Clin Immunol 2000;106:500-6.)
Databáze: OpenAIRE
Externí odkaz: